免疫組織化學市場 - 增長、趨勢和預測 (2023-2028)
市場調查報告書
商品編碼
1273359

免疫組織化學市場 - 增長、趨勢和預測 (2023-2028)

Immunohistochemistry Market - Growth, Trends, and Forecasts (2023 - 2028)

出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內,免疫組織化學市場預計將以 7.3% 左右的複合年增長率增長。

SARS-CoV-2 爆發對早期市場增長產生了重大影響,因為實驗室和研究機構因全球封鎖而面臨試劑供應短缺。 例如,根據 ASCP 2022 年 2 月的更新,對標本管和其他常見實驗室耗材的需求威脅到在大流行期間進行診斷測試的各個方面。 試劑短缺對市場增長產生了重大影響,因為一些研究機構和生物製藥公司正在評估免疫熒光分析,以將其開發為 COVID-19 的有效診斷工具。 SARS-CoV-2 也可以使用 dsRNA 抗體通過 IHC 方法檢測。 由於在大流行後情況下越來越多地使用免疫組織化學來診斷各種慢性疾病,預計未來幾年市場將會增長。

免疫組織化學用於診斷癌症和其他涉及抗原抗體反應的疾病,因此癌症發病率的增加是市場增長的主要驅動力。 例如,根據美國癌症協會 2023 年癌症統計數據,2021 年美國將診斷出 189 萬新癌症患者,而 2023 年將診斷出約 196 萬新癌症患者。 因此,隨著癌症負擔的增加和人們對癌症認識的提高,對早期診斷的需求有望增加,從而推動市場的增長。

此外,免疫組化產品的技術進步有望提高現有產品的效率和有效性,預計這將對預測期內的免疫組化產品需求產生有利影響。 例如,2022 年 7 月,NextCure 發表了一篇論文,使用新開發的抗 Siglec-15 (S15) 抗體和免疫組織化學 (IHC) 測定法研究實體瘤中 S15 的表達。 本文介紹了與耶魯大學醫學院病理學系的研究人員合作進行的一項研究的數據摘要。

此外,預計在預測期內,人口迅速老齡化以及慢性病和傳染病的高負擔將進一步推動對用於診斷和檢測應用的 IHC 產品的需求。 例如,根據聯合國一份2022年的報告,世界老年人口增長迅速,65歲及以上人口占世界人口的比例預計將從2022年的10%上升到2050年的16%。事實已經如此。 由於老年人口更容易患上慢性病,因此相信更多地使用檢測來解決這一問題將導致市場增長。

然而,有限的報銷政策和 IHC 產品的高價格預計會抑制市場增長。

免疫組織化學的市場趨勢

在預測期內,診斷領域預計將佔據免疫組化市場的很大份額

促進診斷領域增長的關鍵因素是多個市場進入者推出新產品、增加即時診斷以及快速發展的技術。 此外,在全球病毒流行病和慢性病中使用診斷技術,以及個性化醫療的開發和後續管理,可能會推動市場增長。 例如,根據疾病預防控制中心 2023 年 1 月的更新,全球已診斷出 85,100 例 Salmodoki 病例。

這一細分市場的巨大份額源於各種慢性疾病的日益突出以及免疫組織化學在傳染病、心血管疾病和其他疾病診斷中的廣泛應用。 例如,根據 2022 年 2 月的一篇 PubMed 論文,波形蛋白免疫染色作為心肌重塑和所有非心肌細胞類型動力學的標誌物,目前用於診斷缺血性心髒病。一些研究表明它可能作為傳統染色的補充有用技巧。 缺血性心髒病和中風是主要原因,佔 CVD 死亡的 80% 以上。

根據 2022 年 8 月發表在 JACC 上的一篇論文,在美國國家健康和營養調查中,中風(33.8% → 1500 萬)和心力衰竭(33.4% → 1300 萬),其次是缺血性心髒病(30.7% → 2900 萬)和心髒病發作(16.9% → 1600 萬)。 因此,使用免疫染色診斷心髒病的應用有望增加對 IHC 產品的需求。

此外,主要參與者的新產品發布、合作夥伴關係、併購以及研究活動的增加等戰略活動預計將進一步推動該細分市場的增長。 例如,2021年6月,Amoy Diagnostics、Riken Genesis和Precision Medicine Asia向市場推出了AmoyDx Pan Lung Cancer PCR Panel。 該面板已獲厚生勞動省批准在日本銷售和製造。 同樣,2021 年 1 月,Thermo Fisher Scientific 收購了一家私營分子診斷公司 Mesa Biotech。 Mesa Biotech 的創新平台將能夠在護理點加速提供具有高可靠性和準確性的先進分子診斷。

免疫組化市場-IMG1

預計在預測期內北美將佔據很大的市場份額

由於主要參與者的存在、癌症和其他慢性病的高患病率以及完善的醫療保健基礎設施等因素,預計在整個預測期內,北美將保持顯著的市場份額。 例如,根據美國心臟協會 2021 年期刊,估計到 2035 年,美國將有超過 1.3 億成年人患有某種形式的心髒病。 同樣,根據加拿大統計局 2022 年的更新,預計加拿大將有 233,900 人被診斷出患有癌症。 對有效診斷解決方案以接受心髒病和癌症充分治療的需求不斷增長,預計將推動北美市場的增長。

此外,根據加拿大對 2022 年的人口預測,近五分之一的加拿大人(佔人口的 18.8%,即 7,329,910 人)將年滿 65 歲。 因此,慢性病的流行以及該國老年人口的增加預計將在預測期內增加免疫化學工具的開發機會。

此外,增加與研究市場相關的新產品發布將促進市場增長。 例如,2021 年 12 月,癌症診斷自動化染色解決方案提供商 BioGenex 宣布了三種用於癌症診斷的新型初級免疫組織化學 (IHC) 抗體。 此外,2021 年 3 月,羅氏將推出 DISCOVERY Green HRP 顯色劑檢測試劑盒,用於癌症研究中的擴展免疫組織化學多重分析。

免疫組化市場-IMG2

免疫組織化學工業概況

免疫組織化學市場競爭激烈,由多家大型企業組成。 市場參與者包括 F. Hoffmann-LA Roche、Agilent Technologies, Inc.、Thermo Fisher Scientific Inc.、Merck Millipore、Abcam PLC、Bio-Rad Laboratories, Inc、PerkinElmer, Inc、Cell Signaling Technology, Inc.、Bio I have an SB .

其他福利:

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第一章介紹

  • 調查假設和市場定義
  • 本次調查的範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 癌症患病率增加
    • 老年人口激增,慢性病和傳染病負擔加重
    • IHC 的技術進步和生物學研究的增加
  • 市場製約因素
    • 高成本 IHC 產品
    • 缺乏適當的報銷政策
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分

  • 按產品分類
    • 抗體
    • 設備
    • 試劑盒和試劑
  • 通過使用
    • 診斷
    • 藥物測試
  • 最終用戶
    • 醫院和診斷中心
    • 學術和研究機構
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東和非洲地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • F. Hoffmann-LA Roche AG
    • Agilent Technologies, Inc.
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Abcam PLC
    • Bio-Rad Laboratories, Inc.
    • PerkinElmer, Inc.
    • Cell Signaling Technology, Inc.
    • Bio SB
    • Danaher Corporation
    • Takara Bio

第7章 市場機會與將來動向

簡介目錄
Product Code: 67929

The immunohistochemistry market is projected to grow at a CAGR of nearly 7.3% over the forecast period.

The SARS-CoV-2 outbreak significantly impacted the market's growth during the initial phase since laboratories, and research institutes faced shortages of reagent supply due to the global lockdown. For instance, as per the ASCP February 2022 update, during the pandemic, the need for specimen tubes and other common laboratory consumables threatened access to all aspects of diagnostic testing. As several research organizations and biopharmaceutical companies evaluated immunofluorescence assay to develop it as an effective diagnostic tool for COVID-19, the reagent shortages hugely impacted the market growth. Moreover, SARS-CoV-2 can also be detected by IHC using a dsRNA antibody. In the post-pandemic situation, the market is expected to rise in the coming years due to the rising utilization of immunohistochemistry in the diagnosis of various chronic diseases.

The major factor contributing to the market's growth is the increase in cancer incidence, as immunohistochemistry is used to diagnose cancer and other diseases including antigen-antibody reactions. For instance, according to the American Cancer Society 2023 Cancer Statistics, it is estimated that about 1.96 million new cases of cancer would be diagnosed in the United States in 2023, as compared to 1.89 million in 2021. Hence, with the increasing burden of cancer and awareness about it, the demand for early diagnostics is expected to increase, thereby boosting growth in the market.

Also, the technological advancements in immunohistochemistry products are likely to improve the efficiency and effectiveness of existing products which is anticipated to have a positive impact on the demand for immunohistochemistry products over the forecast period. For instance, in July 2022, NextCure published a paper that utilized a newly developed antibody to Siglec-15 (S15) and an immunohistochemical (IHC) assay to investigate S15 expression in solid tumors. The publication outlines data from a study conducted in collaboration with researchers in the Department of Pathology at Yale School of Medicine.

Moreover, the rapidly increasing geriatric population and high burden of chronic & infectious diseases are further expected to drive the demand for IHC products for diagnostics and testing applications over the forecast period. For instance, as per a United Nations 2022 report, the global geriatric population is increasing rapidly and the share of the global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. Since the geriatric population is more prone to chronic diseases, a corresponding rise is likely to increase the utilization of tests and thereby lead to market growth.

However, limited reimbursement policies and the high cost of IHC products are anticipated to restrain the market growth.

Immunohistochemistry Market Trends

The Diagnostics Segment is Expected to Hold a Significant Share in the Immunohistochemistry Market Over the Forecast Period

Major factors contributing to the growth of the diagnostic segment are new product launches by several market players, increasing point-of-care diagnostics, and rapidly evolving technology. Furthermore, viral epidemics and chronic diseases worldwide and the use of diagnostic techniques to develop and subsequently administer personalized medicine are likely to boost market growth. For instance, as per the January 2023 update by CDC, 85.1 thousand cases of monkeypox are diagnosed globally.

The large share of this segment is credited to the growing predominance of various chronic diseases and the wide application of immunohistochemistry in the diagnosis of infectious diseases, cardiovascular diseases, and other diseases. For instance, as per an article published in February 2022 in PubMed, a study indicated that immunostaining of vimentin as a marker for myocardial remodeling and the dynamics of all non-myocardial cell types might be useful for supplementing conventional staining techniques currently used in the diagnosis of ischemic heart disease. Ischemic heart disease and stroke are the predominant causes and are responsible for more than 80% of CVD fatalities.

As per an article published in August 2022 in JACC, the United States National Health and Nutrition Examination Survey found that stroke (33.8% to 15 million) and heart failure (33.4% to 13 million) have the highest projected increases in cardiovascular disease rates, followed by ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million) for the projected years 2025 to 2060. Hence, applications to diagnose heart disease using immunostaining are expected to increase the demand for IHC products.

In addition, new product launches, strategic activities like collaborations, mergers, and acquisitions by the key players, and an increase in research activities are further expected to add to the segment's growth. For instance, in June 2021, Amoy Diagnostics Co. Ltd, Riken Genesis Co. Ltd, and Precision Medicine Asia Co. Ltd introduced the AmoyDx Pan Lung Cancer PCR Panel in the market. The panel was approved by the Ministry of Health, Labour, and Welfare (MHLW) for marketing and production in Japan. Similarly, in January 2021, Thermo Fisher Scientific acquired Mesa Biotech, a privately held molecular diagnostic company. Mesa Biotech's innovative platform will enable the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at point-of-care.

Immunohistochemistry Market - IMG1

North America is Anticipated to Hold a Significant Market Share in the Market Over the Forecast Period

North America is expected to hold a notable market share throughout the forecast period due to the factors such as the presence of key players, the high prevalence of cancer and other chronic diseases in the region, and the established healthcare infrastructure. For instance, as stated by the American Heart Association 2021 journal, it is estimated that by the year 2035, more than 130 million adults in the United States will have some type of heart disease. Similarly, as per the Statistics Canada 2022 update, an estimated 233.9 thousand people in Canada are expected to be diagnosed with cancer. The growing demand for effective diagnostic solutions to obtain proper treatment for heart disease and cancer is expected to drive the growth of the market in North America.

In addition, as per Canada's population estimates for 2022, almost one in five Canadians (18.8% of the population; 7,329,910 people) were at least 65 years of age. Hence, the prevalence of chronic diseases coupled with the increasing geriatric population in the country is anticipated to create more opportunities for the development of immunochemistry tools during the forecast period.

Furthermore, an increase in new product launches relating to the market studied boosts the growth of the market. For instance, in December 2021, BioGenex, an automated staining solution provider for cancer diagnostics launched three new primary immunohistochemistry (IHC) antibodies for cancer diagnosis. Furthermore, in March 2021, Roche launched the DISCOVERY Green HRP chromogen detection kit to expand immunohistochemistry multiplexing in cancer research.

Immunohistochemistry Market - IMG2

Immunohistochemistry Industry Overview

The immunohistochemistry market is highly competitive and consists of several major players. Some of the key companies in the market are F. Hoffmann-LA Roche, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Merck Millipore, Abcam PLC, Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Cell Signaling Technology, Inc., and Bio SB.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Cancer
    • 4.2.2 Rapidly Increasing Geriatric Population and High Burden of Chronic & Infectious Diseases
    • 4.2.3 Technological Advancement in IHC and Growing Biological Research
  • 4.3 Market Restraints
    • 4.3.1 High Cost IHC Products
    • 4.3.2 Lack of Proper Reimbursement Policies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size - Value in USD million)

  • 5.1 By Product
    • 5.1.1 Antibodies
    • 5.1.2 Equipment
    • 5.1.3 Kits and Reagents
  • 5.2 By Application
    • 5.2.1 Diagnostics
    • 5.2.2 Drug Testing
  • 5.3 By End-User
    • 5.3.1 Hospitals and Diagnostics Centers
    • 5.3.2 Academic & Research Institutes
    • 5.3.3 Other End-users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 F. Hoffmann-LA Roche AG
    • 6.1.2 Agilent Technologies, Inc.
    • 6.1.3 Thermo Fisher Scientific Inc.
    • 6.1.4 Merck KGaA
    • 6.1.5 Abcam PLC
    • 6.1.6 Bio-Rad Laboratories, Inc.
    • 6.1.7 PerkinElmer, Inc.
    • 6.1.8 Cell Signaling Technology, Inc.
    • 6.1.9 Bio SB
    • 6.1.10 Danaher Corporation
    • 6.1.11 Takara Bio

7 MARKET OPPORTUNITIES AND FUTURE TRENDS